Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Matching Placebo

First Posted Date: 2020-03-04

Last Posted Date: 2025-04-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 620

Registration Number: NCT04294810

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇨🇭
Inselspital Bern, Bern, Switzerland

and more 138 locations

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: Obinutuzumab
Drug: Fludarabine
Drug: Venetoclax
Drug: Cyclophosphamide
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2020-02-26

Last Posted Date: 2025-04-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 166

Registration Number: NCT04285567

Locations: 🇺🇸
Medical Center of Aurora, Aurora, Colorado, United States
🇺🇸
American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸
University of Tennessee Medical Center;Office of Clinical Trials, Knoxville, Tennessee, United States

and more 37 locations

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Atezolizumab
Drug: RO7198457

First Posted Date: 2020-02-12

Last Posted Date: 2021-02-04

Lead Sponsor: Hoffmann-La Roche

Registration Number: NCT04267237

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Phase 2

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: RG7774
Drug: Placebo

First Posted Date: 2020-02-11

Last Posted Date: 2024-01-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 104

Registration Number: NCT04265261

Locations: 🇺🇸
Rand Eye, Deerfield Beach, Florida, United States
🇺🇸
Retina Associates Tucson, Tucson, Arizona, United States
🇺🇸
University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan, United States

and more 65 locations

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor, Unspecified, Adult

Interventions: Drug: RLY-1971

First Posted Date: 2020-02-05

Last Posted Date: 2023-01-31

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 56

Registration Number: NCT04252339

Locations: 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 3 locations

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide
Drug: Placebo

First Posted Date: 2020-02-05

Last Posted Date: 2025-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 490

Registration Number: NCT04256421

Locations: 🇩🇪
LungenClinic Großhansdorf GmbH, Großhansdorf, Germany
🇵🇱
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad, Warszawa, Poland
🇹🇷
Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty, Istanbul, Turkey

and more 115 locations

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Mosunetuzumab (IV)
Drug: Mosunetuzumab (SC)
Drug: Tocilizumab
Drug: Lenalidomide

First Posted Date: 2020-01-29

Last Posted Date: 2025-06-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 237

Registration Number: NCT04246086

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, China
🇫🇷
CHRU de Lille - Hopital Claude Huriez, Lille, France
🇫🇷
CHU Montpellier, Montpellier, France

and more 20 locations

A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Phase 3

Terminated

Conditions: Diffuse, Large B-Cell, Lymphoma

Interventions: Drug: Polatuzumab Vedotin
Drug: Bendamustine
Drug: Placebo
Drug: Rituximab

First Posted Date: 2020-01-22

Last Posted Date: 2023-03-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 42

Registration Number: NCT04236141

Locations: 🇨🇳
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China
🇨🇳
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, China

and more 7 locations

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B

Phase 2

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Nucleos(t)ide (NUC)
Drug: CpAM (RO7049389)
Drug: TLR7 (RO7020531)
Drug: siRNA (RO7445482)
Drug: PD-L1 LNA (RO7191863)
Drug: PEG-IFN

First Posted Date: 2020-01-13

Last Posted Date: 2024-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 281

Registration Number: NCT04225715

Locations: 🇨🇳
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China
🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States

and more 48 locations

A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: entrectinib

First Posted Date: 2020-01-13

Last Posted Date: 2024-08-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT04226833

Locations: 🇨🇿
Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
🇸🇰
Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie, Bratislava, Slovakia
🇭🇺
CRU Hungary Kft, Miskolc, Hungary

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy